We observed a significantly higher incidence of mutations and copy-number loss in tumor suppressors such as TP53, RB1, CDKNA2/B, BIRC2/3, and CDKN2C (Fig. 4a, b and Supplementary Fig. 8a–c), likely due to MM progression. Here, CDKN2C is linked to Miyoshi myopathy.